Aug. 12 at 4:48 PM
Raymond James reiterated
$MNPR Outperform-
$123 and said -- We continue to model ALXN1840 approval and launch in 2027—Remain Outperform rated on MNPR shares following 2Q26 update.
$RARE $PRME ETON Vivet Therapeutics - PFE AZN TELO Orphalan
Raymond James added—All eyes remain focused on the rolling NDA submission for ALXN1840 in Wilson disease, which was recently initiated in July and the company expects to complete in the coming months.
Recall, this allows FDA to receive and begin reviewing specific application sections as they are submitted, but acceptance of the application and PDUFA date assignment cannot occur until the application is complete and fully received.
ALXN1840 does have Fast Track designation, which could lead to a shorter review time once the application is complete.
We continue to model ALXN1840 approval and launch in 2027.
